Phase 1 clinical trial to assess safety and efficacy of NY-ESO-1-specific TCR T cells in HLA-A∗02:01 patients with advanced soft tissue sarcoma

New York esophageal squamous cell carcinoma-1 (NY-ESO-1)-specific T cell receptor (TCR) T cell therapy is effective in tumors with NY-ESO-1 expression, but a safe and effective TCR-T cell therapeutic protocol remains to be improved. Here, we report a phase 1 investigational new drug clinical trial w...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Qiuzhong, Weng, Desheng, Liu, Jiayong, Han, Zhaosheng, Ou, Yusheng, Xu, Bushu, Peng, Ruiqing, Que, Yi, Wen, Xizhi, Yang, Jing, Zhong, Shi, Zeng, Lun, Chen, Aiyuan, Gong, Haiping, Lin, Yanmei, Chen, Jiewen, Ma, Ke, Lau, Johnson Y.N., Li, Yi, Fan, Zhengfu, Zhang, Xing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10439245/
https://www.ncbi.nlm.nih.gov/pubmed/37586317
http://dx.doi.org/10.1016/j.xcrm.2023.101133

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10439245/
https://www.ncbi.nlm.nih.gov/pubmed/37586317
http://dx.doi.org/10.1016/j.xcrm.2023.101133

Ejemplares similares